CHACO Study: Control of Arterial Hypertension in Colombian Patients
CHACO
1 other identifier
observational
1,100
1 country
1
Brief Summary
Epidemiological study (cross-sectional study) in order to determine the patients who present an adequate control of the Blood Pressure (BP), in a population of Colombian patients diagnosed with Arterial Hypertension (AH) and who are under pharmacological treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 27, 2019
CompletedFirst Submitted
Initial submission to the registry
September 13, 2019
CompletedFirst Posted
Study publicly available on registry
September 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2024
CompletedSeptember 23, 2019
September 1, 2019
4.4 years
September 13, 2019
September 20, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Patients with adequate control of the Blood Pressure (BP)
Proportion of patients who present an adequate control of the Blood Pressure (BP)
It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Secondary Outcomes (4)
Demographic analysis
It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Treatment analysis
It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Personal history of diseases
It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Adverse Events related with the treatment
It will be evaluated in each patient (only once, at the time of the interview) throughout the study which is estimated to last 3 years.
Eligibility Criteria
Colombian patients
You may qualify if:
- Age ≥ 18 years
- Prior diagnosis of Arterial Hypertension (AH) ≥ 3 months before
- Patients who are under pharmacological treatment of AH ≥ 3 months before
You may not qualify if:
- The patient has rejected the participation in the study.
- Patients who, in the judgment of the Investigator, do not understand or are not willing to adequately answer the questions.
- Mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Scandinavia Pharma
Bogotá, 110111, Colombia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Javier Castillo, Dr
Scandinavia Pharma
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 13, 2019
First Posted
September 19, 2019
Study Start
June 27, 2019
Primary Completion
December 1, 2023
Study Completion
July 1, 2024
Last Updated
September 23, 2019
Record last verified: 2019-09
Data Sharing
- IPD Sharing
- Will not share